You are here

Study of 83,000 Vets Finds Cardiovascular Benefits to Testosterone Replacement

The results could clarify conflicting results from earlier studies

A Veterans Affairs (VA) database study of more than 83,000 patients found that men whose low testosterone was restored to normal through gels, patches, or injections had a lower risk of heart attack, stroke, or death from any cause compared with similar men who were not treated. The study also found that men who were treated but did not attain normal levels did not see the same benefits as those whose levels did reach normal. 

The findings, published online in the European Heart Journal, may sway the ongoing debate over testosterone therapy’s benefits and risks, especially for the heart. Studies over the past few years have yielded mixed results, although part of that might stem from differing patient populations and research methods.

For example, the new VA study excluded men with a history of heart attacks or strokes, although it did include those with existing heart disease. A much-cited VA database study that was published in the Journal of the American Medical Association  in 2013 looked specifically at men with coronary artery disease; about 20% of the total study group of around 8,700 men had suffered a prior heart attack.

So far, the medical community lacks results from any definitive clinical trial that might provide clear guidance. Meanwhile, the FDA issued guidance earlier in 2015 advising clinicians about the overuse of testosterone therapy and pointing to a possible increased risk of heart attack and stroke.

The new VA study is likely to draw attention because of its large size and relatively long follow-up period.

Rajat Barua, MD, PhD, the paper’s corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating “low T” but not restoring levels to normal doesn’t appear to impart much benefit, at least in terms of cardiovascular risk. Testosterone isn’t prescribed with the goal of improving heart health, but that is a consideration in many cases.

“It is the first study to demonstrate that significant benefit is observed only if the dose is adequate to normalize the total testosterone levels,” Barua and his coauthors wrote. “Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in [heart attack] or stroke and had significantly less benefit on mortality.” Barua is with the Kansas City (Missouri) VA Medical Center and is also an assistant professor of medicine at the University of Kansas.

The study team looked at national data on more than 83,000 men with documented low testosterone, all age 50years  or above, who received VA care between 1999 and 2014. The researchers divided the men into three clinical groups: those who were treated to the point where their total testosterone levels returned to normal (group 1); those who were treated but without reaching normal (group 2); and those who were untreated and remained at low levels (group 3).

Importantly, all three groups were “propensity matched” so the comparisons would be between men with similar health profiles. The researchers took into account a wide array of factors that might affect cardiovascular and overall risk. They included, for example, age, body mass index, various chronic diseases, low-density lipoprotein-cholesterol levels, and the use of aspirin, beta blockers, and statins. The average follow-up across the groups ranged from 4.6 to 6.2 years.

The sharpest contrast emerged between group 1 (those who were treated and attained normal levels) and group 3 (those whose low testosterone went untreated). The treated men were 56% less likely to die during the follow-up period, 24% less likely to suffer a heart attack, and 36% less likely to have a stroke. The differences between group 1 and group 2 (those who were treated but did not attain normal levels) were similar but less pronounced. Little difference emerged between groups 2 and 3, except for a slight benefit in survival for those who were treated.

Source: Veterans Affairs Research Communications; August 10, 2015.

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM